Nordstrom co-president Blake Nordstrom diagnosed with lymphoma
Blake Nordstrom said he will undergo chemotherapy over the next few months in Seattle. Doctors have told him he can continue to work throughout this process. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 10, 2018 Category: Health Management Authors: Coral Garnick Source Type: news

Nordstrom co-president Blake Nordstrom diagnosed with lymphoma
Blake Nordstrom said he will undergo chemotherapy over the next few months in Seattle. Doctors have told him he can continue to work throughout this process. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2018 Category: Biotechnology Authors: Coral Garnick Source Type: news

ASH Poster Rounds: Adding BTK Inhibitor Safe in First-Line MCL
(MedPage Today) -- Plus: Lenalidomide upfront in PTCL; skipping RT in primary mediastinal B-cell lymphoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2018 Category: Hematology Source Type: news

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III  MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news

Another Rituximab Biosimilar Passes Lymphoma Test
(MedPage Today) -- Noninferior to EU-licensed agent in randomized trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news

Gene Signature Identifies New Subgroup of DLBCL
A new study has identified a clinically and biologically distinct subgroup of diffuse large B-cell lymphoma tumors. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

ASH: A + CHP Bests CHOP for Peripheral T - Cell Lymphoma
Median progression - free survival improved with A + CHP vs CHOP; similar incidence of adverse events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Does HIV increase cancer risk?
HIV can weaken a person ’s immune system, which can increase the risk of certain types of cancer. Such cancers include Kaposi’s sarcoma, non-Hodgkin lymphoma, and cervical, lung, anal, and oral cancer. However, effective treatment can significantly reduce the risk of developing these cancers. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news

Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients
Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
MONDAY, Dec. 3, 2018 -- For heavily pretreated patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), response rates are high for treatment subsequent to checkpoint blockade therapy (CBT), according to two... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52 percent of those patients responded favorably to the therapy. Forty percent had a complete response and 12 percent had a partial response. (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

New tool to find and fight most dangerous types of lymphoma
(University of Leeds) UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Combination immunotherapy shows high activity against recurrent Hodgkin lymphoma
(NYU Langone Health / NYU School of Medicine) A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

High-cost Gilead cell therapy proves durable for some lymphoma patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

At two years, Gilead lymphoma therapy active in 40 percent of patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial
(University of Texas M. D. Anderson Cancer Center) A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
(Dana-Farber Cancer Institute) New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

New two-year data show 39 percent of NHL patients treated with CAR T remain in remission
(H. Lee Moffitt Cancer Center& Research Institute) A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta ® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
(University of Chicago Medical Center) An international phase-2 trial of a CAR-T cell therapy--to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)--found that 52 percent of patients responded favorably to the therapy; 40 percent had a complete response and 12 percent had a partial response. One year later, 65 percent percent of those patients were relapse-free, including 79 percent of complete responders. The median progression-free survival 'has not been reached.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
(University of Pennsylvania School of Medicine) In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah ® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news

Studies suggest immunotherapy adds punch to earlier attempts
(NYU Langone Health / NYU School of Medicine) New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat drug therapies whose initial attempts failed to stop or reverse the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2018 Category: Cancer & Oncology Source Type: news

New study highlights CAR T-cell therapy success for lymphoma when used as standard of care
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt Cancer Center partnered with 16 academic cancer centers to analyze real world data of 274 patients treated commercially with Yescarta ® (axicabtagene ciloleucel), one of two CAR T products that is now standard of care for patients with diffuse large B cell lymphoma (DLBCL) who have not responded to two or more therapies. The researchers then compared those figures with results from the pivotal ZUMA-1 trial, which included 101 patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2018 Category: Cancer & Oncology Source Type: news

Non-Hodgkin Lymphoma | Medscape Non-Hodgkin Lymphoma | Medscape
Non-Hodgkin lymphoma is the fifth most common cancer in the United States, accounting for about 4% of all malignancies in both men and women. The disease comprises a variety of cancers of the lymphatic system exclusive of Hodgkin lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
Title: Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma DrugCategory: Health NewsCreated: 11/28/2018 12:00:00 AMLast Editorial Review: 11/29/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 29, 2018 Category: Cancer & Oncology Source Type: news

FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

First Biosimilar Rituximab for Lymphoma Approved in US First Biosimilar Rituximab for Lymphoma Approved in US
Truxima, designed for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma, can be used as a single agent or in combination with chemotherapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first biosimilar to Roche's cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin ’s Lymphoma
November 28, 2018 -- The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

U.S. FDA approves first biosimilar to Roche's cancer drug Rituxan
The U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan available in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said today. Truxima, as with Rituxan, is approved to treat... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’ s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’ s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday. A biosimilar is a biological product that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 28, 2018 Category: General Medicine Source Type: news

Efficacy of Rituximab Biosimilar in Follicular Lymphoma
A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

R-Chop Viable For First-Line Tx of follicular lymphoma?
A study investigates whether R-Chop is a viable first-line treatment for patients with advanced follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Chemo-Free Regimen Feasible for Indolent Lymphoma
(MedPage Today) -- No chemo for 10 years for almost 40% with follicular lymphoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 26, 2018 Category: Hematology Source Type: news

What's Hot at This Year's ASH Meeting? What's Hot at This Year's ASH Meeting?
Big results from big trials in leukemia and lymphoma will be presented and are'almost certainly going to be practice changing,'says American Society of Hematology (ASH) Secretary Robert Brodsky, MD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

I Won a Historic Lawsuit, But May Not Live to Get the Money
Dewayne Anthony Lee Johnson has always just gone by Lee. He lived a modest life for 42 years, and was devastated when he was diagnosed with terminal cancer in 2014. Now 46, as he struggles with his advancing illness, Johnson has found sudden celebrity with a historic victory over one of the world’s most powerful and controversial corporations – Monsanto Co. Johnson sued Monsanto alleging that he developed a deadly form of non-Hodgkin lymphoma after being drenched with the company’s herbicides, which he sprayed as part of his job as school groundskeeper. In Aug. 2018, a jury in San Francisco unanimously f...
Source: TIME: Health - November 21, 2018 Category: Consumer Health News Authors: Carey Gillam Tags: Uncategorized Cancer monsanto Source Type: news

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
In this study, we established both phosphoproteomic and gene expression profiles of ALK activity in neuroblastoma cells exposed to first- and third-generation ALK TKIs, to identify the underlying molecular mechanisms and identify relevant biomarkers, signaling networks, and new therapeutic targets. This analysis has unveiled various important leads for novel combinatorial treatment strategies for patients with neuroblastoma and an increased understanding of ALK signaling involved in this disease. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Van den Eynden, J., Umapathy, G., Ashouri, A., Cervantes-Madrid, D., Szydzik, J., Ruuth, K., Koster, J., Larsson, E., Guan, J., Palmer, R. H., Hallberg, B. Tags: STKE Research Resources Source Type: news

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
Oncogenic anaplastic lymphoma kinase (ALK) is one of the few druggable targets in neuroblastoma, and therapy resistance to ALK-targeting tyrosine kinase inhibitors (TKIs) comprises an inevitable clinical challenge. Therefore, a better understanding of the oncogenic signaling network rewiring driven by ALK is necessary to improve and guide future therapies. Here, we performed quantitative mass spectrometry–based proteomics on neuroblastoma cells treated with one of three clinically relevant ALK TKIs (crizotinib, LDK378, or lorlatinib) or an experimentally used ALK TKI (TAE684) to unravel aberrant ALK signaling pathway...
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Emdal, K. B., Pedersen, A.-K., Bekker-Jensen, D. B., Lundby, A., Claeys, S., De Preter, K., Speleman, F., Francavilla, C., Olsen, J. V. Tags: STKE Research Resources Source Type: news

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
MONDAY, Nov. 19, 2018 -- The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: World Pharma News)
Source: World Pharma News - November 19, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

First Results of Beat AML Master Trial Published
The ground-breaking study, led by the Leukemia& Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 16, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news